Deals
AbbVie Faces Extended U.S. Antitrust Review for Allergan Deal
Allergan Inc. Botox
Photographer: Patrick T. Fallon/Bloomberg
This article is for subscribers only.
AbbVie Inc.’s deal to buy Botox maker Allergan Plc will undergo an in-depth investigation by U.S. antitrust enforcers.
The companies said Friday that they received a second request for information from the Federal Trade Commission about the proposed $63 billion tie-up. The request extends the antitrust review by the agency beyond an initial 30-day period.